Journal: Cancers

Article Title: Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells

doi: 10.3390/cancers14246214

Figure Lengend Snippet: Bioenergetic fingerprints of non-tumorigenic and tumorigenic EMT (I). Left panels: Bioenergetic metabolites from non-tumorigenic HMLE-EMT and tumorigenic HMLER-EMT mesenchymal cells were extracted and quantitatively analyzed by GC-EI-QTOF-MS and compared with those in non-tumorigenic HMLE and tumorigenic HMLER parental counterparts. Significantly increased and decreased metabolites (EMT vs. epithelial controls) are shown using brown-red and light blue-dark blue color scales, respectively. Middle panels: Two-dimensional score plots of the partial least square discriminant analysis (PLS-DA) models of the GC-EI-QTOF-MS-based bioenergetic metabolomic profiling of HMLE/HMLE-EMT and HMLER/HMLER-EMT cells. The X and Y axes represent the combinations of the different bioenergetic metabolites analyzed, showing the maximum separation between groups. Right panels: Key bioenergetic metabolites separating the metabolomic profiles of HMLE/HMLE-EMT and HMLER/HMLER-EMT cells based on variable importance in projection (VIP) in PLS-DA analysis described in the middle panels. The VIP score, which is calculated as a weighted sum of the squared correlations between PLS-DA components and the original variable, summarizes the contribution of the metabolites’ importance in the PLS-DA model. The number of terms in the sum depends on the number of PLS-DA components found to be significant in distinguishing the classes.

Article Snippet: Cells were cultured in a 1:1 mixture of MEGM (Mammary Epithelial Bullet Kit, ref. H3CC-3150; Lonza, Basel, Switzerland) and DMEM/F12 supplemented with 10% fetal bovine serum (FBS), insulin (10 μg/mL), hydrocortisone (0.5 μg/mL), hEGF (10 ng/mL), 1% L-glutamine, and penicillin/streptomycin (Sigma, Madrid, Spain).

Techniques:

Journal: Cancers

Article Title: Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells

doi: 10.3390/cancers14246214

Figure Lengend Snippet: Homocysteine–methionine 1C metabolism fingerprints of non-tumorigenic and tumorigenic EMT (I). Left panels: Homocysteine–methionine 1C metabolites from non-tumorigenic HMLE-EMT and tumorigenic HMLER-EMT mesenchymal cells were extracted and quantitatively analyzed by UHPLC-ESI-QqQ-MS/MS and compared with those of non-tumorigenic HMLE and tumorigenic HMLER parental counterparts. Significantly increased and decreased metabolites (EMT vs. epithelial controls) are shown using brown-red and light blue-dark blue color scales, respectively. Middle panels: Two-dimensional score plots of the partial least square discriminant analysis (PLS-DA) models of the UHPLC-ESI-QqQ-MS/MS-based homocysteine–methionine 1C metabolomic profiling of HMLE/HMLE-EMT and HMLER/HMLER-EMT cells. The X and Y axes represent the combinations of the different 1C metabolites analyzed, showing the maximum separation between groups. Right panels: Key 1C metabolites separating the homocysteine–methionine 1C metabolomic profiles of HMLE/HMLE-EMT and HMLER/HMLER-EMT cells based on variable importance in projection (VIP) in PLS-DA analysis described in the middle panels. The VIP score, which is calculated as a weighted sum of the squared correlations between PLS-DA components and the original variable, summarizes the contribution of the metabolites’ importance in the PLS-DA model. The number of terms in the sum depends on the number of PLS-DA components found to be significant in distinguishing the classes.

Article Snippet: Cells were cultured in a 1:1 mixture of MEGM (Mammary Epithelial Bullet Kit, ref. H3CC-3150; Lonza, Basel, Switzerland) and DMEM/F12 supplemented with 10% fetal bovine serum (FBS), insulin (10 μg/mL), hydrocortisone (0.5 μg/mL), hEGF (10 ng/mL), 1% L-glutamine, and penicillin/streptomycin (Sigma, Madrid, Spain).

Techniques: Tandem Mass Spectroscopy